AmpliPhi Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies
AmpliPhi Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies Targeting C. Difficile
RICHMOND, Virginia & COLWORTH, England & SYDNEY--(BUSINESS WIRE)-- AmpliPhi BioSciences Corporation (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, announces it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile (C. difficile), a serious gastrointestinal infection for which new treatments are urgently required.
Under the terms of the agreements, AmpliPhi will fund Dr Martha Clokie's team at the University of Leicester to progress non-clinical studies of bacteriophage products as an alternative to treating antibiotic resistant infections caused by C. difficile bacteria. Evaluations of the efficacy of bacteriophage therapy will be carried out at the University of Glasgow, UK, in the laboratory of Dr Gill Douce, under a three-way collaborative project between AmpliPhi, Leicester and Glasgow. C. difficile infection is widely accepted to be the leading cause of hospital-acquired (or nosocomial) infection-related morbidity and mortality, outpacing both antibiotic-resistant staphylococcus (MRSA) and enterococcus (VRE). Community-acquired cases also appear to be increasing in incidence. Figures released by the US Center for Disease Control in its September 2013 report on antibiotic resistance, classed C. difficile as an urgent threat, causing 250,000 infections in the US every year and costing $1 billion a year in excess medical costs.
The team at the University of Leicester has discovered phages that have been shown to be effective against clinically-relevant strains of C. difficile isolated from around the world. AmpliPhi will license the patents, materials and know-how related to these discoveries from the University of Leicester and, rights, title and interest to any future intellectual property developed under this collaboration will belong to AmpliPhi. Furthermore, AmpliPhi will have exclusive rights to certain background intellectual property of the University of Leicester, for which AmpliPhi will make milestone payments based on product development and pay royalties based on product sales.
Philip J. Young, CEO of AmpliPhi said "C. difficile causes at least 14,000 deaths a year in the US alone. We are very excited to be working with both the UK based teams to continue the development of innovative bacteriophage therapies. The progress has been impressive to date. We believe that this is the only phage based development program for this critical indication. Developing a treatment for C. difficile is in keeping withour global strategy to develop bacteriophage therapies for the rapidly escalating problem of antibiotic resistance."
About AmpliPhi BioSciences
AmpliPhi BioSciences Corporation [OTCBB:APHB] is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics for human and animal applications. The Company's product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments. AmpliPhi was created in 2011 through the merger of BioControl Ltd with Targeted Genetics Inc. and subsequent combination with Special Phage Services in 2012. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com
Forward Looking Statements
Statements in this press release about the potential use of bacteriophages to treat bacterial infections and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency.
For more information regarding AmpliPhi:
The Shoreham Group LLC
+1 212 242 7777
Media Enquiries - College Hill Life Sciences
Gemma Howe / Stefanie Bacher - UK
+44 20 7457 2020
Sue Charles - Managing Partner - Global
+44 (0)7968 726585 (UK)
+61 (0)466 924218 (AUS)
+1 347 448 3210 (USA)
Dr Douglas Pretsell - AUS
+61 (0)466 925 966
KEYWORDS: Australia United Kingdom United States Europe North America Australia/Oceania Virginia
The article AmpliPhi Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies Targeting C. Difficile originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.